These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35606018)

  • 1. Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity.
    Sun F; Zhao L; Wang H; Zhang D; Chen J; Wang X; Li T; Ye S
    Lupus Sci Med; 2022 May; 9(1):. PubMed ID: 35606018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
    Hao Y; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Zhang Z
    Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
    Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
    Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
    Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
    Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort.
    Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Quintana R; Gómez-Puerta JA; Catoggio LJ; Alvarellos A; Saurit V; Borba E; Sato E; Costallat L; Da Silva NA; Iglesias-Gamarra A; Neira O; Reyes-Llerena G; Cardiel MH; Amigo MC; Acevedo-Vásquez E; Esteva-Spinetti MH; Alarcón GS; Pons-Estel BA
    J Rheumatol; 2019 Oct; 46(10):1299-1308. PubMed ID: 30824636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study.
    Fasano S; Coscia MA; Pierro L; Ciccia F
    Lupus; 2021 May; 30(6):991-997. PubMed ID: 33709836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
    Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Catoggio LJ; Drenkard C; Sarano J; Berbotto GA; Borba EF; Sato EI; Tavares Brenol JC; Uribe O; Ramirez Gómez LA; Guibert-Toledano M; Massardo L; Cardiel MH; Silveira LH; Chacón-Diaz R; Alarcón GS; Pons-Estel BA;
    Ann Rheum Dis; 2017 Dec; 76(12):2071-2074. PubMed ID: 28939626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
    Thanou A; Chakravarty E; James JA; Merrill JT
    Rheumatology (Oxford); 2014 Dec; 53(12):2175-81. PubMed ID: 24729400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low disease activity state associated with fewer incident vertebral fractures in Mestizo women with systemic lupus erythematosus.
    Mendoza-Pinto C; Etchegaray-Morales I; Munguía-Realpozo P; Osorio-Peña ÁD; Méndez-Martínez S; Ramírez-Lara E; Zárate-Arellano D; Solis-Poblano JC; Ayón-Aguilar J; García-Carrasco M
    Lupus; 2023 Oct; 32(11):1328-1334. PubMed ID: 37705367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroconversion to antinuclear antibody negativity and its association with disease flare in patients with systemic lupus erythematosus.
    Kwon OC; Kim YG; Park JH; Park MC
    Lupus; 2020 Jun; 29(7):697-704. PubMed ID: 32279583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.
    Ho A; Magder LS; Barr SG; Petri M
    Arthritis Rheum; 2001 Oct; 44(10):2342-9. PubMed ID: 11665975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low frequency of flares during pregnancy and post-partum in stable lupus patients.
    Davis-Porada J; Kim MY; Guerra MM; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Sawitzke A; Merrill JT; Buyon JP; Salmon JE
    Arthritis Res Ther; 2020 Mar; 22(1):52. PubMed ID: 32188491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting flares in patients with stable systemic lupus erythematosus.
    Cho J; Lahiri M; Teoh LK; Dhanasekaran P; Cheung PP; Lateef A
    Semin Arthritis Rheum; 2019 Aug; 49(1):91-97. PubMed ID: 30660381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial.
    Mathian A; Pha M; Haroche J; Cohen-Aubart F; Hié M; Pineton de Chambrun M; Boutin THD; Miyara M; Gorochov G; Yssel H; Cherin P; Devilliers H; Amoura Z
    Ann Rheum Dis; 2020 Mar; 79(3):339-346. PubMed ID: 31852672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiological and immunological profile of patients with severe lupus flares related to bloodstream infections: a retrospective cohort study.
    Torres-Ruiz J; Barrera-Vargas A; Ortiz-Hernández R; Alcocer-Varela J; Ponce-de-León A; Gómez-Martín D
    Lupus; 2018 Feb; 27(2):312-318. PubMed ID: 28699377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flares in pediatric systemic lupus erythematosus.
    Weiss JE; Sison CP; Ilowite NT; Gottlieb BS; Eberhard BA
    J Rheumatol; 2007 Jun; 34(6):1341-4. PubMed ID: 17477466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
    Zen M; Saccon F; Gatto M; Montesso G; Larosa M; Benvenuti F; Iaccarino L; Doria A
    Rheumatology (Oxford); 2020 Jul; 59(7):1591-1598. PubMed ID: 31642908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
    Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
    Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Better Health-Related Quality of Life in Systemic Lupus Erythematosus Predicted by Low Disease Activity State/Remission: Data From the Peruvian Almenara Lupus Cohort.
    Ugarte-Gil MF; Gamboa-Cárdenas RV; Reátegui-Sokolova C; Medina-Chinchón M; Zevallos F; Elera-Fitzcarrald C; Pimentel-Quiroz V; Cucho-Venegas JM; Rodríguez-Bellido Z; Pastor-Asurza CA; Alarcón GS; Perich-Campos R
    Arthritis Care Res (Hoboken); 2020 Aug; 72(8):1159-1162. PubMed ID: 31199590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.